Literature DB >> 20844871

In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer's disease.

Masamichi Yokokura1, Norio Mori, Shunsuke Yagi, Etsuji Yoshikawa, Mitsuru Kikuchi, Yujiro Yoshihara, Tomoyasu Wakuda, Genichi Sugihara, Kiyokazu Takebayashi, Shiro Suda, Yasuhide Iwata, Takatoshi Ueki, Kenji J Tsuchiya, Katsuaki Suzuki, Kazuhiko Nakamura, Yasuomi Ouchi.   

Abstract

PURPOSE: Amyloid β protein (Aβ) is known as a pathological substance in Alzheimer's disease (AD) and is assumed to coexist with a degree of activated microglia in the brain. However, it remains unclear whether these two events occur in parallel with characteristic hypometabolism in AD in vivo. The purpose of the present study was to clarify the in vivo relationship between Aβ accumulation and neuroinflammation in those specific brain regions in early AD.
METHODS: Eleven nootropic drug-naïve AD patients underwent a series of positron emission tomography (PET) measurements with [(11)C](R)PK11195, [(11)C]PIB and [(18)F]FDG and a battery of cognitive tests within the same day. The binding potentials (BPs) of [(11)C](R)PK11195 were directly compared with those of [(11)C]PIB in the brain regions with reduced glucose metabolism.
RESULTS: BPs of [(11)C](R)PK11195 and [(11)C]PIB were significantly higher in the parietotemporal regions of AD patients than in ten healthy controls. In AD patients, there was a negative correlation between dementia score and [(11)C](R)PK11195 BPs, but not [(11)C]PIB, in the limbic, precuneus and prefrontal regions. Direct comparisons showed a significant negative correlation between [(11)C](R)PK11195 and [(11)C]PIB BPs in the posterior cingulate cortex (PCC) (p < 0.05, corrected) that manifested the most severe reduction in [(18)F]FDG uptake.
CONCLUSION: A lack of coupling between microglial activation and amyloid deposits may indicate that Aβ accumulation shown by [(11)C]PIB is not always the primary cause of microglial activation, but rather the negative correlation present in the PCC suggests that microglia can show higher activation during the production of Aβ in early AD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20844871     DOI: 10.1007/s00259-010-1612-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  39 in total

1.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.

Authors:  Brian J Lopresti; William E Klunk; Chester A Mathis; Jessica A Hoge; Scott K Ziolko; Xueling Lu; Carolyn C Meltzer; Kurt Schimmel; Nicholas D Tsopelas; Steven T DeKosky; Julie C Price
Journal:  J Nucl Med       Date:  2005-12       Impact factor: 10.057

2.  Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease.

Authors:  J Steven Jacobsen; Chi-Cheng Wu; Jeffrey M Redwine; Thomas A Comery; Robert Arias; Mark Bowlby; Robert Martone; John H Morrison; Menelas N Pangalos; Peter H Reinhart; Floyd E Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-20       Impact factor: 11.205

3.  Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study.

Authors:  Paul Edison; Hilary A Archer; Alexander Gerhard; Rainer Hinz; Nicola Pavese; Federico E Turkheimer; Alexander Hammers; Yen Fong Tai; Nick Fox; Angus Kennedy; Martin Rossor; David J Brooks
Journal:  Neurobiol Dis       Date:  2008-08-15       Impact factor: 5.996

4.  Anti-inflammatory drugs and Alzheimer disease.

Authors:  P L McGeer; E McGeer; J Rogers; J Sibley
Journal:  Lancet       Date:  1990-04-28       Impact factor: 79.321

5.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

Authors:  Henry Engler; Anton Forsberg; Ove Almkvist; Gunnar Blomquist; Emma Larsson; Irina Savitcheva; Anders Wall; Anna Ringheim; Bengt Långström; Agneta Nordberg
Journal:  Brain       Date:  2006-07-19       Impact factor: 13.501

6.  Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory.

Authors:  Ganesh M Shankar; Shaomin Li; Tapan H Mehta; Amaya Garcia-Munoz; Nina E Shepardson; Imelda Smith; Francesca M Brett; Michael A Farrell; Michael J Rowan; Cynthia A Lemere; Ciaran M Regan; Dominic M Walsh; Bernardo L Sabatini; Dennis J Selkoe
Journal:  Nat Med       Date:  2008-06-22       Impact factor: 53.440

Review 7.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

8.  Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.

Authors:  Clayton A Wiley; Brian J Lopresti; Sriram Venneti; Julie Price; William E Klunk; Steven T DeKosky; Chester A Mathis
Journal:  Arch Neurol       Date:  2009-01

9.  Altered glucose metabolism in the hippocampal head in memory impairment.

Authors:  Y Ouchi; S Nobezawa; H Okada; E Yoshikawa; M Futatsubashi; M Kaneko
Journal:  Neurology       Date:  1998-07       Impact factor: 9.910

10.  Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls.

Authors:  N M Scheinin; S Aalto; J Koikkalainen; J Lötjönen; M Karrasch; N Kemppainen; M Viitanen; K Någren; S Helin; M Scheinin; J O Rinne
Journal:  Neurology       Date:  2009-09-02       Impact factor: 9.910

View more
  59 in total

Review 1.  Potential Therapeutical Contributions of the Endocannabinoid System towards Aging and Alzheimer's Disease.

Authors:  Amandine E Bonnet; Yannick Marchalant
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

2.  The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.

Authors:  E Cavedo; S Lista; Z Khachaturian; P Aisen; P Amouyel; K Herholz; C R Jack; R Sperling; J Cummings; K Blennow; S O'Bryant; G B Frisoni; A Khachaturian; M Kivipelto; W Klunk; K Broich; S Andrieu; M Thiebaut de Schotten; J-F Mangin; A A Lammertsma; K Johnson; S Teipel; A Drzezga; A Bokde; O Colliot; H Bakardjian; H Zetterberg; B Dubois; B Vellas; L S Schneider; H Hampel
Journal:  J Prev Alzheimers Dis       Date:  2014-12

Review 3.  Immune-mediated processes in neurodegeneration: where do we stand?

Authors:  Marc Fakhoury
Journal:  J Neurol       Date:  2016-02-12       Impact factor: 4.849

4.  Brain PET Poster Sessions PP01-M01 to PP02-N07.

Authors: 
Journal:  J Cereb Blood Flow Metab       Date:  2019-07       Impact factor: 6.200

Review 5.  Targeting innate immunity for neurodegenerative disorders of the central nervous system.

Authors:  Katrin I Andreasson; Adam D Bachstetter; Marco Colonna; Florent Ginhoux; Clive Holmes; Bruce Lamb; Gary Landreth; Daniel C Lee; Donovan Low; Marina A Lynch; Alon Monsonego; M Kerry O'Banion; Milos Pekny; Till Puschmann; Niva Russek-Blum; Leslie A Sandusky; Maj-Linda B Selenica; Kazuyuki Takata; Jessica Teeling; Terrence Town; Linda J Van Eldik
Journal:  J Neurochem       Date:  2016-09       Impact factor: 5.372

Review 6.  New and Old TSPO PET Radioligands for Imaging Brain Microglial Activation in Neurodegenerative Disease.

Authors:  Laura Best; Christine Ghadery; Nicola Pavese; Yen Foung Tai; Antonio P Strafella
Journal:  Curr Neurol Neurosci Rep       Date:  2019-04-02       Impact factor: 5.081

Review 7.  Imaging Translocator Protein as a Biomarker of Neuroinflammation in Dementia.

Authors:  William C Kreisl; Ioline D Henter; Robert B Innis
Journal:  Adv Pharmacol       Date:  2017-11-10

8.  Curcumin/melatonin hybrid 5-(4-hydroxy-phenyl)-3-oxo-pentanoic acid [2-(5-methoxy-1H-indol-3-yl)-ethyl]-amide ameliorates AD-like pathology in the APP/PS1 mouse model.

Authors:  Gorka Gerenu; Kai Liu; Jeremy E Chojnacki; John M Saathoff; Pablo Martínez-Martín; George Perry; Xiongwei Zhu; Hyoung-Gon Lee; Shijun Zhang
Journal:  ACS Chem Neurosci       Date:  2015-05-04       Impact factor: 4.418

Review 9.  In vivo PET imaging of neuroinflammation in Alzheimer's disease.

Authors:  Julien Lagarde; Marie Sarazin; Michel Bottlaender
Journal:  J Neural Transm (Vienna)       Date:  2017-05-17       Impact factor: 3.575

10.  Reduced glucose uptake and Aβ in brain regions with hyperintensities in connected white matter.

Authors:  L Glodzik; A Kuceyeski; H Rusinek; W Tsui; L Mosconi; Y Li; R S Osorio; S Williams; C Randall; N Spector; P McHugh; J Murray; E Pirraglia; S Vallabhajosula; A Raj; M J de Leon
Journal:  Neuroimage       Date:  2014-07-04       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.